Log in

NASDAQ:GMABGenmab A/S Stock Price, Forecast & News

$30.52
+1.22 (+4.16 %)
(As of 05/26/2020 04:00 PM ET)
Add
Compare
Today's Range
$30.48
Now: $30.52
$31.02
50-Day Range
$20.22
MA: $25.17
$29.40
52-Week Range
$16.24
Now: $30.52
$31.02
Volume827,893 shs
Average Volume1.05 million shs
Market Capitalization$19.92 billion
P/E Ratio16.41
Dividend YieldN/A
BetaN/A
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GMAB
CUSIPN/A
CIKN/A
Phone45-7020-2728

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$804.57 million
Cash Flow$0.55 per share
Book Value$3.26 per share

Profitability

Net Income$324.68 million

Miscellaneous

Employees419
Market Cap$19.92 billion
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive GMAB News and Ratings via Email

Sign-up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter.

Genmab A/S (NASDAQ:GMAB) Frequently Asked Questions

How has Genmab A/S's stock been impacted by COVID-19 (Coronavirus)?

Genmab A/S's stock was trading at $20.60 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GMAB stock has increased by 48.2% and is now trading at $30.52. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Genmab A/S?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Genmab A/S.

When is Genmab A/S's next earnings date?

Genmab A/S is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Genmab A/S.

How were Genmab A/S's earnings last quarter?

Genmab A/S (NASDAQ:GMAB) issued its quarterly earnings results on Wednesday, May, 6th. The company reported $0.06 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.02 by $0.04. The company earned $131.69 million during the quarter, compared to analyst estimates of $133.04 million. Genmab A/S had a net margin of 41.69% and a return on equity of 19.19%. View Genmab A/S's earnings history.

What guidance has Genmab A/S issued on next quarter's earnings?

Genmab A/S updated its FY 2020 After-Hours earnings guidance on Wednesday, May, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $665-721 million, compared to the consensus revenue estimate of $717.17 million.

What price target have analysts set for GMAB?

10 analysts have issued 12 month price targets for Genmab A/S's shares. Their forecasts range from $23.00 to $30.00. On average, they expect Genmab A/S's share price to reach $27.80 in the next twelve months. This suggests that the stock has a possible downside of 8.9%. View analysts' price targets for Genmab A/S.

Has Genmab A/S been receiving favorable news coverage?

News headlines about GMAB stock have been trending extremely positive this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Genmab A/S earned a media sentiment score of 5.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutGenmab A/S.

Who are some of Genmab A/S's key competitors?

What other stocks do shareholders of Genmab A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include Alibaba Group (BABA), Home Depot (HD), Verizon Communications (VZ), Cisco Systems (CSCO), CVS Health (CVS), Honeywell International (HON), Johnson & Johnson (JNJ), AT&T (T), Walmart (WMT) and Pfizer (PFE).

Who are Genmab A/S's key executives?

Genmab A/S's management team includes the following people:
  • Dr. Jan G. J. van de Winkel, Co-Founder, Pres & CEO (Age 58)
  • Mr. David A. Eatwell, Exec. VP & CFO (Age 58)
  • Dr. Judith V. Klimovsky, Exec. VP & Chief Devel. Officer (Age 61)
  • Mr. Peter Storm Kristensen, Associate Director of Legal & Non-Independent Director (Age 44)
  • Mr. Daniel J. Bruno, VP of Corp. Controller & Non-Independent Director (Age 39)

When did Genmab A/S IPO?

(GMAB) raised $503 million in an initial public offering on Thursday, July 18th 2019. The company issued 27,800,000 shares at $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers.

What is Genmab A/S's stock symbol?

Genmab A/S trades on the NASDAQ under the ticker symbol "GMAB."

Who are Genmab A/S's major shareholders?

Genmab A/S's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (0.38%), Redmile Group LLC (0.24%), Waddell & Reed Financial Inc. (0.24%), Federated Hermes Inc. (0.16%), Wells Fargo & Company MN (0.14%) and Viking Global Investors LP (0.13%).

Which institutional investors are selling Genmab A/S stock?

GMAB stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management LLC, Federated Hermes Inc., Balyasny Asset Management LLC, Pentwater Capital Management LP, Dubuque Bank & Trust Co., King Wealth, Bank of New York Mellon Corp, and Cutter & CO Brokerage Inc..

Which institutional investors are buying Genmab A/S stock?

GMAB stock was bought by a variety of institutional investors in the last quarter, including Waddell & Reed Financial Inc., Redmile Group LLC, BlackRock Inc., Jennison Associates LLC, Viking Global Investors LP, Tekla Capital Management LLC, 1832 Asset Management L.P., and ETRADE Capital Management LLC.

How do I buy shares of Genmab A/S?

Shares of GMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Genmab A/S's stock price today?

One share of GMAB stock can currently be purchased for approximately $30.52.

How big of a company is Genmab A/S?

Genmab A/S has a market capitalization of $19.92 billion and generates $804.57 million in revenue each year. The company earns $324.68 million in net income (profit) each year or $0.51 on an earnings per share basis. Genmab A/S employs 419 workers across the globe.

What is Genmab A/S's official website?

The official website for Genmab A/S is www.genmab.com.

How can I contact Genmab A/S?

Genmab A/S's mailing address is Kalvebod Brygge 43, Copenhagen G7, 1560. The company can be reached via phone at 45-7020-2728 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.